About Tirzepatide Report
An evidence-based, drug-focused guide to tirzepatide.
Edited by Alan Pierce, Clinical Pharmacology Writer. Alan Pierce is Tirzepatide Report's clinical pharmacology writer, covering tirzepatide's mechanism, trials, dosing, and safety using primary research and official labeling. Coverage of costs and access also draws on official provider, clinic and government sources.
What we publish
Our research library draws on registration trials, peer-reviewed research and FDA labeling for medical information, plus official provider, clinic and government sources for costs and access. Articles carry numbered references so you can check the underlying evidence.
Alongside it we keep a commercial layer, because the practical question after “does this drug work” is always “where do I get it and what will it cost.” Our provider comparisons describe price transparency, clinical oversight, and support. Affiliate partners appear first in our main provider list; that placement is not an independent quality score. Our tirzepatide price index publishes the underlying figures — each one carrying the dose it applies at and whether the product is brand or compounded — as a table, a CSV, and a JSON feed. The same reviews also feed a trust & verification index — which LegitScript badges we traced to LegitScript’s own CDN, which FDA warning-letter claims checked out against FDA’s own database, and which providers name their compounding pharmacy.
How we check prices, handle corrections, and account for commercial relationships in provider placement are set out in our editorial policy.
Contact
Questions, corrections, or editorial feedback are welcome. Reach the Tirzepatide Report team at contact@tirzepatidereport.com.